Halo Pharma Names Laurent Malgouyres Site Director for Mirabel, Canada Facility

Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, has appointed Laurent Malgouyres as Site Director for its cGMP facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance.

Malgouyres has worked in the pharmaceutical industry for over 14 years, most recently serving as Vice President of Operations at Omega Laboratories/Juno Pharmaceuticals in Canada. His previous work leadership roles include positions at Pharmascience, where he managed FDA- and Health Canada-approved sites that employed more than 200 people. Throughout his career, he has successfully led initiatives to increase production capacity, implement operational efficiency processes, and execute major capital investment projects.

“Laurent has a track record of establishing autonomous, high-performing teams while fostering a culture of operational excellence, continuous improvement, and human development that align with our core beliefs and objectives at Halo Pharma,” says Lee Karras, CEO of Noramco, parent company of Halo Pharma. “Laurent’s experience and vision will be instrumental as we continue to strengthen our manufacturing capabilities and position Halo Pharma for long-term growth.”

Halo Pharma’s Mirabel site opened more than 40 years ago and has served as a center of pharmaceutical development and manufacturing excellence, offering solid dose, bulk powder, oral liquid, and suppository development and manufacturing.

“I’m honored to join Halo Pharma and lead the talented team in Mirabel,” said Malgouyres. “The site has a strong legacy of quality and innovation, and I look forward to building on that foundation as we continue to enhance our capabilities and deliver value to our customers.”

For more information about Halo Pharma, visit https://halopharma.com.

About Halo Pharma
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA and Montreal, Quebec, Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharma’s capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information, please contact services@halopharma.com.

Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

Company Contact
Halo Pharma & Woodstock Sterile Solutions
Stacy London
Stacy.london@wssterile.com